Pivotal Therapeutics Inc.
PVTTF
Get informed when a big investor buys or sells
+ FollowMarket Cap$172.43K
Close$
Share Statistics
| Market cap | $172,430.00 |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | -79.54 |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Pivotal Therapeutics, Inc.
CEO: Rachelle MacSweeney Pivotal Therapeutics, Inc. is a pharmaceutical company, which engages in the optimization of Omega-3 therapy for cardiovascular disease and overall health. Its products include Benefishial, Omazen, and Vascazen. The company was founded b...